Published guidance, NICE advice and quality standards | Guidance

Showing 341 to 350 of 875

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	TA779	16 March 2022	16 March 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction	TA773	9 March 2022	9 March 2022
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)	TA774	9 March 2022	9 March 2022
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea	TA776	9 March 2022	9 March 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea	TA777	9 March 2022	9 March 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria	TA778	9 March 2022	9 March 2022
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies	TA772	23 February 2022	23 February 2022
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)	TA771	9 February 2022	9 February 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	TA770	9 February 2022	9 February 2022
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable	TA763	2 February 2022	2 February 2022